These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 5260856)

  • 1. [Chronic myelogenous leukemia. Results of therapy with busulfan].
    Olesen J; Videbaek A
    Nord Med; 1969 Oct; 82(41):1284-90. PubMed ID: 5260856
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ambulatory treatment of patients with chronic myeloid leukemia].
    Lobanova NA
    Ter Arkh; 1981; 53(9):25-8. PubMed ID: 6946602
    [No Abstract]   [Full Text] [Related]  

  • 3. [Course and prognosis of chronic myeloid leukemia treated with busulfan. Study of 300 cases].
    Ionescu V
    Dtsch Med Wochenschr; 1971 May; 96(20):867-70. PubMed ID: 5280862
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of chronic myeloid leukemia with repeated single doses of busulfan.
    Sullivan JR; Hurley TH; Bolton JH
    Cancer Treat Rep; 1977; 61(1):43-5. PubMed ID: 266418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observations on the therapy of chronic granulocytic leukaemia (C.G.L.) in adults.
    Das KV; Thomas M; Pilla MV; Vijayakumar
    J Assoc Physicians India; 1977 Aug; 25(8):547-53. PubMed ID: 275251
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical effects of Vercyte(A-803) on chronic myelogenous leukemia].
    Kinugasa K; Takaku F; Sasa S; Mizoguchi H; Komine M
    Naika; 1971; 28(1):151-6. PubMed ID: 5284419
    [No Abstract]   [Full Text] [Related]  

  • 7. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation.
    Ferrara F; Palmieri S; Annunziata M; Viola A; Pocali B; Califano C; D'Arco AM; Mele G
    Bone Marrow Transplant; 2004 Oct; 34(7):573-6. PubMed ID: 15258559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The possibility of radical chemotherapy in chronic myelocytic leukaemia.
    Galton DA
    Haematol Lat; 1969; 12(3):703-9. PubMed ID: 5273182
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of chronic myeloid leukemia with dibromomannitol].
    Clément F; Saillen R
    Schweiz Med Wochenschr; 1970 Nov; 100(46):1995-7. PubMed ID: 5279364
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy of the blastic crisis].
    Tura S; Baccarani M; Bagnara GP
    Minerva Med; 1972 Mar; 63(24):1459-67. PubMed ID: 4502509
    [No Abstract]   [Full Text] [Related]  

  • 11. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic myeloid leukemia treated with busulfan. Clinical characteristics, prognostic factors, effect of treatment and survival in 82 cases].
    Larrain C; Cruz A; Codoceo V
    Rev Med Chil; 1984 Sep; 112(9):898-911. PubMed ID: 6598227
    [No Abstract]   [Full Text] [Related]  

  • 13. [Differential diagnosis of atypical chronic myeloid leukaemia].
    Klein UE; Schwarze EW; Schwalbe P; Tolksdorf ME
    Dtsch Med Wochenschr; 1976 Jun; 101(24):915-20. PubMed ID: 1064523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Remarks on the course and prognostic factors in a series of chronic myeloid leukemia].
    Furno F; Neretto G; Mazza A; Giovanelli E; Agricola R; Martinetto P
    Arch Sci Med (Torino); 1980; 137(3):499-506. PubMed ID: 6940518
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
    Martino R; Pérez-Simón JA; Moreno E; Queraltó JM; Caballero D; Mateos M; Sureda A; Cañizo C; Brunet S; Briones J; Vazquez L; Clopés A; San Miguel JF; Sierra J
    Biol Blood Marrow Transplant; 2005 Jun; 11(6):437-47. PubMed ID: 15931632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [On the tactics of myelosan therapy of chronic myeloleukosis].
    Kassirskiĭ IA; Volkova MA
    Ter Arkh; 1967 Feb; 39(2):3-9. PubMed ID: 5252300
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pulmonary fibrosis after busulfan therapy].
    Jandl H; Franke A; Albrecht G
    Z Gesamte Inn Med; 1975 Dec; 30(24):799-801. PubMed ID: 1062873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical conference: Thrombocythemic introduction to chronic myeloid leukemia].
    Bauters F; Goudemand M
    Nouv Rev Fr Hematol; 1975; 15(2):241-4. PubMed ID: 126433
    [No Abstract]   [Full Text] [Related]  

  • 19. [Aplastic syndrome in myleran overdose].
    Albrecht M; Tackmann W; Pribilla W
    Med Klin; 1971 Jan; 66(4):126-30. PubMed ID: 5278287
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pregnancy during busulfan therapy of chronic granulocytic leukemia].
    Szentcsíki M; Brenner F; Balogh C; Hites L
    Orv Hetil; 1982 May; 123(21):1307-8. PubMed ID: 6955735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.